All In Biotech

Drug Trial Radar · NCT01678898

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Months to Adult Fabry Patients

Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Oct 2012

Primary completion

Mar 6, 2016

Study completion Mar 6, 2016

Sponsor

Lead sponsor
ProtalixIndustry
Sponsor type
Industry
Collaborators
Chiesi Farmaceutici S.p.A.
First posted
Sep 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first human treatment with PRX-102, an enzyme being developed as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be evaluated in this study of increasing doses. Patients will be treated with infusions every two weeks for 12 months.

Conditions

  • Fabry Disease

Interventions

  • PRX-102Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 12 months

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics

    Sacramento, California

  • Department of Human Genetics, Emory University School of Medicine

    Atlanta, Georgia

  • University of Iowa Health Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Duke University Medical Center

    Durham, North Carolina

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Research Baylor Institute of Metabolic Disease

    Dallas, Texas

  • O & O Alpan LLC

    Fairfax, Virginia

  • Royal Melbourne Hospital

    Victoria Park, Australia

  • Hematology and Clinical Research Private Institute

    Asunción, Paraguay

  • Clinical Center of Serbia

    Belgrade, Serbia

  • Hospital de Dia Quiron Zaragoza

    Zaragoza, Spain

  • The Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.